Enrollment completed in Leber’s hereditary optic neuropathy trial

10:30 EDT 2 Aug 2017 | Healio

Enrollment has been completed in a phase 3 clinical trial of a treatment for Leber’s hereditary optic neuropathy, according to a press release from GenSight Biologics.The RESCUE randomized, double-masked, sham-controlled multicenter trial will evaluate a single intravitreal injection of GS010, designed to treat Leber’s hereditary optic neuropathy caused by a mutation in the ND4 gene, in 37 patients, the release said.

Original Article: Enrollment completed in Leber’s hereditary optic neuropathy trial


More From BioPortfolio on "Enrollment completed in Leber’s hereditary optic neuropathy trial"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...